← Back to Search

VB-201 for Inflammation

Phase 1 & 2
Waitlist Available
Research Sponsored by Priscilla Hsue, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year (change from baseline to week 24 and baseline to week 52)
Awards & highlights

Study Summary

This study is evaluating whether a drug called VB-201 can reduce inflammation in people with HIV.

Eligible Conditions
  • Inflammation
  • HIV/AIDS
  • Cardiovascular Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year (change from baseline to week 24 and baseline to week 52)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year (change from baseline to week 24 and baseline to week 52) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Target-to-background ratio (TBR)
Secondary outcome measures
Change in D-Dimer (ng/mL)
Change in Interleukin-6 (IL-6) in pg/mL
Change in Lipoprotein (a) [Lp(a)] in mg/dL
+5 more
Other outcome measures
Change in high risk plaque
Change in non-calcified plaque progression
Incidence of new lesions

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: VB-201Experimental Treatment1 Intervention
One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
Group II: PlaceboPlacebo Group1 Intervention
One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VB-201
Not yet FDA approved

Find a Location

Who is running the clinical trial?

University of UtahOTHER
1,099 Previous Clinical Trials
1,778,689 Total Patients Enrolled
10 Trials studying Inflammation
804 Patients Enrolled for Inflammation
Priscilla Hsue, MDLead Sponsor
3 Previous Clinical Trials
198 Total Patients Enrolled
2 Trials studying Inflammation
164 Patients Enrolled for Inflammation
University of California, Los AngelesOTHER
1,530 Previous Clinical Trials
10,278,202 Total Patients Enrolled
26 Trials studying Inflammation
2,858 Patients Enrolled for Inflammation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial
Priscilla Hsue, MD 2022. "Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04939311.
~0 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top